The emergence of the biotechnology industry and introduction of drugs derived from recombinant DNA technology has generated many new issues in approaches to preclinical safety evaluation and extrapolation of results to risk assessment in humans. Products or therapeutic approaches for consideration include hormones, growth factors, cytokines, monoclonal antibodies, vaccines, blood products, antisense, and gene therapy. In many instances the application of standard safety tests conventionally used for small molecules are of limited value or are inappropriate. Studies should be designed to answer specific scientific questions rather than simply to fulfill regulatory requirements. Special consideration must be given to study design and species selection in terms of biological activity and species specificity, implications of immunological responses in the animal studies, and effects of systemic administration of molecules at clinically relevant doses. A full understanding of the clinical relevance of toxicological and pathologic findings associated with administration of these molecules to laboratory animals requires definition of the pathogenic mechanism of lesion induction.
INTRODUCTION
The emergence of the biotechnology industry and introduction of drugs derived from genetic engineering has generated many novel issues in approaches to preclinical safety evaluation and extrapolation of results to risk assessment in humans.
A number of natural endogenous proteins such as hormones, enzymes, cytokines, and growth factors as well as monoclonal antibodies and vaccines produced by recombinant DNA and hybridoma technology are commercially available for potential therapeutic use. Thus, a definition of biotechnology products can include all medicinal products obtained by recombinant DNA techniques, hybridoma techniques for obtaining monoclonal antibodies, use of primary and continuous cell lines, and synthetically made peptides to be used for diagnostic or therapeutic purposes or for vaccination (5) . Early experience suggested that animal models were not effective in predicting the adverse effects of these macromolecules subsequently observed in humans (28, 34) , largely due to the species-specific nature of the compounds that were first studied. The specific proteins were tested in nonhomologous species in which they had reduced or no biological activity and the potential for immunogenicity. The majority of the available biotechnology products represent peptide sequences identical to natural human proteins, and the development of antibody responses in animals treated with the products can lead in some cases to rapid and sustained neutralization and clearance of the test substance or hypersensitivity reactions that restrict the usefulness and duration of animal safety studies (36). As a result of early experiences, the appropriateness of preclinical safety studies conducted with recombinant products has been questioned (3 1): However, with increased experience with a large number of biotechnologp products, it has become evident that well-designed preclinical studies conducted in pharmacologically responsive animal models do provide important safety information (16).
The use of recombinant DNA methods for manufacture of a human therapeutic product does not, in and of itself, introduce any unique requirements for toxicological studies (35). Products derived from biotechnology manufacturing techniques face the same regulatory review procedures and submission 187 requirements as pharmaceutical products manufactured through more traditional techniques (4). In the United States, the Center for Biological Evaluation and Research in the Food and Drug Administration (FDA) is the primary group that regulates biotechnology products. In addition, the FDA has addressed a number of issues and concerns specific to the manufacture and testing of biological products for human use in a series ofinformal documents referred to as "Points to Consider" (Table I) . These documents do not represent guidelines or regulations but, rather, identify some of the special considerations that developers of biotechnology products must be aware of during product development in order to secure registration and licensure. The issues addressed in these FDA guidelines are also relevant to regulatory concerns in other countries.
SPECIAL CONSIDERATIONS IN TESTING OF
RECOMBINANT MOLECULES The level of preclinical safety testing required for a recombinant molecule intended for therapeutic use in humans will depend on the characterization of the product, what is known of its biological activities, and its intended clinical use. It is important to determine the similarity of the molecule to the endogenous substance. A molecule that is identical to an endogenous compound, and that will be used at physiologic doses, may not require extensive animal testing. If the molecule is to be used as replacement therapy in a deficiency state, such as the case with insulin or growth hormone, it is likely to be of less concern than a product intended for use at pharmacological or exaggerated doses. This is particularly true if there is sufficient knowledge and experience with clinical use of the natural substances.
The toxicological testing of monoclonal antibodies involves many problems similar to those with recombinant proteins. Thsse antibodies are often directed at specific tissue antigens or receptors that are not expressed in animals, so that results of animal experiments cannot easily be extrapolated to humans (22) . Also, because of the antigenicity of monoclonal antibodies for the animals, the development of an antibody response complicates repeated administration and makes long-term studies difficult or impossible. Therefore, it is essential to consider each product individually and to design studies that take advantage of all available knowledge about the structure and activity ofthe molecule and that will address safety issues in the context of the proposed clinical use. A number of issues must be considered in the design and interpretation of safety studies with biotechnology products, and these are illustrated and discussed in detail herein.
POTENTIAL MECHANISMS OF TOXICITY
The toxicological pathologist is frequently at an advantage in interpreting and understanding the pathogenesis of lesions observed with biotechnology products because there is an abundant wealth of knowledge about the biological activities of many of these molecules compared to the information available about activities of small chemical entities. Many of the effects, both desirable and adverse, of biotechnology products are receptor-mediated. In some instances, such as for transforming growth factor-& (TGF-8,) (30) , receptors are widely distributed in a variety of organs and cell types, but the proteins are normally present or produced in very small quantities at specific sites. Systemic administration of recombinant proteins such as these at high doses may result in exaggerated pharmacodynamic responses that would not be expected at physiologic doses, especially if the protein is normally produced and exerts its effect locally. Receptor induction at nontarget sites may also result in unwanted physiological effects. Conversely, down-regulation of receptors could occur, blocking the ability of the receptor to respond to normal stimulation.
An example of a case where the pathogenesis of lesiom associated with systemic administration of a molecule can be p>edicted based on the known biologic activities of the molecule can be illustrated with interleukin-1 (IL-1). IL-1 actually represents 2 distinct molecules, IL-la and IL-10, both of which bind to a common receptor (9). Safety studies with recombinant human ILla in cynomolgus monkeys resulted in severe systemic toxicity and mortality (3). Histopathological lesions included thymic atrophy and hypocellularity of lymphoid organs, inflammatory lesions in the liver, kidney, eye, and adrenal gland, myocardial and renal degeneration with mineral deposition, and osteoclastic bone resorption. Based on known biological activities of IL-I, the probable pathogenesis of the majority of these lesions can be defined. IL-1 induces fever by stimulation of prostaglandin E2 production in the hypothalamus (1 1) and stimulates increased endogenous corticosteroid production through activation of the hypothalamic-pituitary-adrenal axis (26) . Elevated corticosteroid levels could account for the lymphoid atrophy. The activities of IL-1 are proinflammatory @), but it also induces the production of other growth factors and cytokines, including tissue necrosis factor (TNF); colony-stimulating factor (CSF); interleukin-6 (IL-6), interleukin-2 (IL-2), and interleukin-4; and the interferons (6). This cascade effect of IL-1 on cytokine production may contribute to the inflammatory reactions observed in multiple organs. Systemic administration of IL-1 has been shown to induce severe hypotension in rabbits and primates (12, 20) . Hypotension would cause decreased perfusion of visceral organs, possibly leading to ischemic injury. IL-1 induced increased bone resorption (1 5,25), resulting in elevated plasma calcium and phosphorus levels, would set up an environment conducive for mineral deposition, particularly in sites of tissue damage secondary to ischemia. A thorough understanding of the pathogenesis of lesions observed in the test species and knowledge of the comparative biological activities of the molecule in humans and the different species is essential for determining the relevance of these lesions to the clinical situation.
HOST CELL CONTAMINANTS
Material used for preclinical studies must be produced under conditions that ensure the purity and integrity of the product and should be identical to, or equivalent to, the material to be used in clinical studies. Although the presence of contaminants introduced into the test material in the manufacturing process have to be considered, this is an issue better addressed through analytical procedures than interpretation of pathological findings. The primary concerns are for presence of viral particles, DNA from the host cell system, endotoxin, or manufacturing reagents introduced during the purification and recovery process. It is important to demonstrate that the purity of the product is greater than 95%, and that no single protein impurity is present in excess of 1% of the total protein. Mammalian cell lines used to produce recombinant proteins also may secrete cytokines, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colonystimulating factor (GM-CSF). High levels of IL-6 have been identified in several vaccines and recom-binant DNA-derived protein formulations (1 3). IL-1 and T N F have been identified in some monoclonal antibody preparations. If unexpected resultsare obtained in preclinical safety studies, the possibility of impurities has to be considered. Although initially host cell contaminants were thought to present a major safety concern, the cell culture and purification/recovery technologies have advanced to the point in most experienced companies that strict adherence to proper manufacturing technique usually will minimize these concerns.
SPECIES SELECTION
One of the single most important considerations in designing the preclinical safety program is selection of the test species. Often, the adverse effects seen in toxicity studies with cytokines and growth factors are exaggerated pharmacological effects of the molecules; therefore, they can only be studied in a responsive species (1 8). The species tested should be one in which the molecule has pharmacological activity the same as in humans. This largely depends on the degree of homology of the molecules or their receptors between humans and the different species tested. Some cytokines and growth factors, including TGF-@,, interleukin-8, and G-CSF, are highly conserved and have activity across species (19, 23, 30) . Other cytokines, IL-2 and IL-6 show less homology between human and murine proteins, but the human molecules are active in rodents (18, 24) . IL-1 and T N F are examples of cytokines that have activity across species, although the level of activity ofthe human protein is diminished in rodent species (2 1). This allows for testing of the efficacy and toxicity of the molecules in experimental animals including rodents. However, some cytokines and growth factors have a very restricted host range of activity (species-specific), including the interferons, GM-CSF, and interleukin-3 (1 8, 3 1). For speciesspecific proteins, testing of the recombinant human molecule in animals may be of limited value for predicting human toxicity.
For example, human interferon-y (IFN-y) is active on human cells and to a lesser extent on nonhuman primate cells, but not on cells of other mammalian species such as the mouse and rat (1). The protein sequknces of murine IFN-y and human IFN-y have only 40% homology (7), and this low homology of the proteins may explain the restricted host range for response to human IFN-y. The principal acute toxicity of the interferons in humans consists of a flu-like syndrome characterized by fever, chills, myalgias, arthralgias, and headaches (29). Manifestations of hematological toxicity include leukopenia, anemia, and thrombocytopenia. Liver toxicity is observed in some patients. Gastrointes-TOXICOLOGIC PATHOLOGY tinal toxicity is characterized by anorexia, nausea, vomiting, and diarrhea. Safety studies conducted in rats with recombinant human interferon-y (rhIFNy) revealed no evidence of toxicity at any dose tested. This is not surprising considering the lack of homology between rodent and human IFN-y. Toxicity studies in cynomolgus monkeys with rhIFN-y resulted in generalized systemic toxicity characterized by fever, lethargy, anorexia, and changes in hematology and serum chemistry values, which are comparable to the changes observed in humans with interferon therapy. In addition, significant histopathological lesions were also observed in muItiple organ systems following high-dose treatment (32). These data indicate that the cynomolgus monkey is responsive to the biological activities of rhIFN-y, albeit at a decreased level of sensitivity compared to humans, and if doses are escalated high enough, the potential clinical toxicity of the recombinant molecule can be characterized in this heterologous species. Monkeys treated with rhIFN-y for 3 mo developed glomerulonephritis consistent with an immune complex pathogenesis. These animals had detectable antibody titers against rhIFN-y, and it is possible that the glomerulonephritis was secondary to this antibody response. The neutralizing antibody response to rhIFN-y in the cynomolgus monkeys appeared to ameliorate many of the effects of the treatment. A comparative study was conducted in mice with recombinant murine IFN-y (rmuIFN-y) to evaluate IFN-y in a homologous species. In this study, the nature of the treatment-related lesions and organ systems affected were similar to observations made in the primates treated with the human protein (17) . No evidence of an antibody response was observed in mice treated with the rmuIFN-y, indicating that studies oflonger duration could be possible in this homologous system. These results suggest that studies employing a recombinant protein in a homologous species may provide a useful model for evaluation of safety for proteins of high species specificity. IMMUNOGENICITY It would be expected that an immune response would be elicited in most animal species following exposure to natural or recombinant human proteins. If an antibody is elicited, it is important to determine the nature of the antibody formed and to consider the immune response in interpretation of the lesions observed. An antibody response may produce anaphylaxis or immune complex disease, or it may affect the pharmacokinetics of the molecule or neutralize its activity. This can limit the utility of animal model systems for multiple dose or chronic studies. It does not necessarily predict the risk for immunogenicity of the molecule in humans, however, because an immune response in the clinic either may not occur or may be attenuated. There is currently not a good system to evaluate the potential immunogenicity of a recombinant molecule in humans. A number of therapeutic proteins and peptides have been shown to induce an immune response in humans (16), but it generally is not the limiting factor in the clinical use of the protein. One possible exception is in the use of murine monoclonal antibodies as therapeutics. Over 50% of the patients treated with murine monoclonals develop human anti-murine antibody (HAMA) responses, which may limit their use as therapeutics (4, 27) .
To avoid the HAMA response, a variety of strategies have been attempted in modification of the murine antibody. One approach is the use of human monoclonal antibodies; however, human antibodies are difficult to make outside of the body. Alternate approaches involve altering the antibodies through genetic or protein engineering to make them more humanized and less immunogenic in humans. The immunoglobulin variable domain from the murine antibody may be joined to human constant domains (chimeric antibody), just the antigen recognition region from the murine immunoglobulin may be transplanted onto a human structural antibody (humanized monoclonal), or amino acids in the murine framework of the antibody molecule can be substituted (veneering) while keeping the antigen-binding determinant intact. While these approaches have been shown to decrease the immunogenicity of the antibodies in humans and in primates (lo), animal toxicity testing with the humanized antibody may become less relevant due to increased immunogenicity and decreased specificity in the test species.
EXPERIMENTAL DFSIGN Biotechnology products are frequently directed at special target populations, and the nature ofthe molecule, dose regimen, and target population should be factors in defining the safety protocol. As indicated earlier, many of the macromolecules have multiple biological effects. The desired therapeutic effect may be targeted at 1 cell type or localized activity, but systemic exposure can result in activities at a variety of sites and organs. In addition, the pharmacological effects of systemic exposure to the proteins can contribute to the adverse effects observed. Therefore, frequently the greatest challenge is determining the best system for delivery of the :molecule to the specific target site in a manner to optimize its activity at that site and to minimize the systemic effects. It is imperative that the proposed clinical plan for the use of a molecule be known before the preclinical safety studies are attempted.
In addition to determining the doses for the safety studies, the duration, frequency, and route of dosing should mimic as closely as possible the clinical plan.
TGF-@ is an example ofa molecule with biological activities affecting a wide variety of tissues, and receptors for TGF-@ are ubiquitous. I n viro, TGF-@ stimulates collagen synthesis and deposition of extracellular matrix by fibroblasts and enhances neovascularization, properties that would be expected to result in acceleration ofthe normal wound healing process (30). Based on this demonstrated activity, recombinant human transforming growth factor-@, (rhTGF-0,) was evaluated for its potential use as a wound-healing agent. A pilot toxicity study was conducted in the rat using a research grade formulation administered by daily intravenous injections at doses up to 1,000 pg/kg/day. Deaths were observed at the high dose after 5 days of treatment, and systemic histopathological lesions were observed in multiple target tissues including liver, bone, kidney, heart, thymus, pancreas, and intestine (33). Although the majority of these lesions can be attributed to known biological activities of TGF-@,, the severity of the lesions precluded systemic administration at these doses. Studies in animal models demonstrated that topical administration of rhTGF-@, to open wounds is effective in accelerating wound healing, and the enhanced wound healing observed follows a biphasic response with optimal results at doses of 15-25 ng of rhTGF-C), applied to the wound (2). Based on these data, the planned clinical use involved topical application of rhTGF-@, to open wounds at very low doses. Subsequent safety studies were conducted where the rhTGF-P, was applied to wound sites in rats and rabbits to mimic the clinical exposure. Studies were also conducted to evaluate systemic toxicity at doses lower than those used in the pilot study since systemic absorption following topical exposure is minimal. These studies demonstrated that rhTGF-@, is well tolerated and resulted in no systemic toxicity following high-dose dermal exposure. The adverse effects observed at high doses in the pilot study would have little relevance to safety following the intended clinical exposure, illustrating the need to carefully design safety studies to mimic the clinical studies. TISSUE CROSS-REACTIVITY A unique concern regarding the safety of monoclonal-based therapeutics is that the target antigen, or an immunologically related epitope, may be expressed on cells other thanthe intended target tissue and lead to undesirable cross-reactions and tissue damage. This is illustrated by the clinical experience with the 260F9 monoclonal antibody-recombinant ricin A chain immunotoxin (14) . This antibody re-acts with approximately 50% of breast carcinomas. Patients treated with the immunotoxin developed debilitating sensorimotor neuropathies. The effect was not predicted in preclinical primate studies. It was subsequently demonstrated that the monoclonal antibody targeted the Schwann cells, resulting in demyelination and neuropathy. To minimize the risk of cross-reactions, an antibody binding study is generally required by the FDA before a product can enter clinical trials (4). This involves an immunohistochemical survey of human organs, blood components, and intended target cells and tissues to evaluate potential cross-reactive binding activity. For murine monoclonal antibodies, the use of indirect immunoperoxidase techniques makes this a very sensitive tool for evaluation of tissue crossreactivity. However, if humanized monoclonal antibodies are tested, there is a decrease in sensitivity of the assay due to the technical limitations of using an anti-human immunoglobulin as a secondary antibody in an indirect immunoperoxidase staining procedure on human tissue sections. If binding to human tissues is detected, studies should be conducted to determine the in iivo sequellae of this binding in an animal species that shares the same cross-reactive antigen, if possible. Similar immunohistochemical cross-reactive binding studies should be conducted on tissue sections from the test animal system.
CONCLUSIONS
The objective of the preclinical safety testing program for any pharmaceutical product is to identify and understand the potential toxic effects of the test material in the most relevant system available. The availability of modem recombinant DNA techniques for production and manufacture of therapeutic products offers promise for a large number of molecules that otherwise could not be produced in sufficient quantities for testing and treatment. Recombinant proteins are complex molecules that often have diverse effects on many different cell types and organ systems. The conventional experimental models used for safety assessment of new drugs cannot be applied indiscriminately to the evaluation of biotechnology pfoducts. Each protein is unique, and the design of the most appropriate preclinical testing program must be considered on a case-by-case basis. The adverse effects of these materials are often the result of exaggerated pharmacological activity. It is important that consideration be given .to selection of the most relevant species, route of administration, and immunogenicity of the molecule be given in designing the safety program. If toxicity is observed in the animal test system, an attempt should be made to understand mechanisms. With carefully
